No Data
No Data
Enlivex Therapeutics | 6-K/A: Report of foreign private issuer (related to financial reporting)
Express News | Enlivex Therapeutics Ltd - No Serious Adverse Reactions Reported in Phase I Safety Run-in
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy
H.C. Wainwright Maintains Enlivex Therapeutics(ENLV.US) With Buy Rating, Maintains Target Price $6
Enlivex Therapeutics Financials Indicate Net Loss
Enlivex Therapeutics Price Target Announced at $13.00/Share by EF Hutton
No Data
No Data